Neuralstem Inc., a Germantown biopharmaceutical company working on treatments for nervous system diseases, was awarded two patents by the U.S. Patent and Trademark Office. One patent covers ways of treating neurodegenerative disorders through transplantation of neural stem cells. The other covers ...

Tagged with: Montgomery County neuralstem

Neuralstem Inc., a biopharmaceutical company, recently received a grant worth up to nearly $1 million from the National Institutes of Health. The Germantown company received the research grant, to evaluate over two years the ability of its small molecule compound, NSI-189 to prevent and ...

Tagged with: biotech germantown Montgomery County neuralstem

Germantown-based Neuralstem Inc., a biopharmaceutical firm developing treatments for nervous system diseases on Thursday announced plans to raise less than $6 million through an underwritten public offering. Neuralstem will offer 3 million shares of common stock and warrants to purchase up to 2.25 ...

Tagged with: germantown Montgomery County neuralstem

A Maryland biopharmaceutical company on Tuesday announced mixed results for its phase 2 clinical trial of its experimental antidepressant. The study, by Germantown-based Neuralstem Inc. of its NSI-189 drug, given once and twice daily to treat major depressive disorder, didn’t show ...

Tagged with: germantown Montgomery County neuralstem

Neuralstem Inc. can thank the discovery of a 1991 agreement among three inventors for a federal judge’s dismissal Wednesday of a multimillion-dollar claim that the Germantown-based biotech company infringed a California firm’s patent on a spinal treatment.

Tagged with: neuralstem patent infringement Stem cells

Neuralstem, of Germantown, a biotechnology company that produces stem-cell treatments for central nervous system diseases and conditions, reported a bigger loss for 2014 than in 2013. Neuralstem posted a net loss of $22.6 million, or 26 cents per share, compared ...

Tagged with: neuralstem

Neuralstem Inc., a Germantown-based biotechnology company, narrowed its loss in the third quarter. Neuralstem reported a net loss of $4.5 million, or 5 cents per share, compared with $6.7 million, or 9 cents, for the same period in 2013. The ...

Tagged with: earnings neuralstem

Neuralstem Inc., of Germantown, a biotechnology company, announced that the first patient was treated last week in the Phase I trial testing its NSI-566 human neural stem cells for chronic spinal cord injury. The trial occurred at the UC San ...

Tagged with: neuralstem stem cell trial

Neuralstem Inc., of Rockville, which develops products to treat central nervous system disorders with patented stem cell technology, announced the closing of a $20 million registered direct placement of approximately 6.87 million shares of common stock at a price of $2.91 per share.

Tagged with: breaking news maryland neuralstem rockville stock Stocks

Neuralstem Inc., of Rockville, a biotherapeutic company developing products to treat central nervous system disorders with patented stem cell technology, reported a second-quarter net loss of $6.25 million, or 9 cents per share, compared to a net loss of $2.5 million, or 4 cents per share, in the prior-year period.

Tagged with: Business earnings maryland neuralstem rockville